Praxbind idarucizumab regulatory update

EMA’s CHMP recommended approval of Praxbind idarucizumab from Boehringer to reverse the anticoagulant effect of Pradaxa dabigatran etexilate mesylate. On April 20, Boehringer said FDA granted Priorit...